Zhenfan Yang

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: Dizal (Jiangsu) Pharmaceutical Co., Ltd., Dizal (Jiangsu) Pharmaceutical Co., Ltd., Astrazeneca Ab. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhenfan Yang. Retrieved from https://idiyas.com/inventor/zhenfan-yang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 94.1

CIPO Patents = 1 (Patent Applications = 15)

EPO Patents = 5 (Patent Applications = 18)

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 16(Granted Patents)

Company Filing History:

6 out of 15

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

patents

4 out of 4

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal (Jiangsu) Pharceutical Co., Ltd.

patent

5. 3 out of 834,601

Other

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Anti-FGFR2B Antibodies

DNA-dependent Protein Kinase Inhibitor

BTK Inhibitors

JAK1 Selective Kinase Inhibitor

ErbB Inhibitors

Triazolo-pyrimidine Compounds

Pyrazine Compounds

Quinazoline Inhibitors

Epidermal Growth Factor Receptor

Cancer Treatment

Kinase Inhibition

Therapeutic Compounds

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774337 - NOVEL ANTI-FGFR2B ANTIBODIES (2026-10-27),

2. 12723091 - NOVEL ANTI-FGFR2B ANTIBODIES (2026-09-01),

3. 12630565 - DNA-dependent protein kinase inhibitor (2026-05-19),

4. 12624039 - BTK inhibitors (2026-05-12),

5. 12606544 - JAK1 selective kinase inhibitor (2026-04-21),

6. 11896597 - ErbB/BTK inhibitors (2024-02-13),

7. 11629147 - Triazolo-pyrimidine compounds and uses thereof (2023-04-18),

8. 11571420 - Pyrazine compounds and uses thereof (2023-02-07),

9. 11504375 - ErbB/BTK inhibitors (2022-11-22),

10. 11447492 - ERBB receptor inhibitors (2022-09-20),

11. 11007198 - ErbB/BTK inhibitors (2021-05-18),

12. 10898481 - Pyrazine compounds and uses thereof (2021-01-26),

13. 10858365 - Triazolo-pyrimidine compounds and uses thereof (2020-12-08),

14. 10822334 - ErbB receptor inhibitors (2020-11-03),

15. 9718806 - Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor (2017-08-01),

Title: **Innovative Contributions of Inventor Zhenfan Yang from Shanghai, CN**

Introduction

Zhenfan Yang is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 12 patents, he has dedicated his career to developing innovative treatments that target critical health issues, particularly cancer.

Latest Patents

Zhenfan Yang's latest patents exhibit his expertise in the development of compounds that inhibit ErbB and BTK proteins. One notable invention focuses on compounds that inhibit ErbBs, such as EGFR and Her2, particularly their mutant forms. These compounds are represented as pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers and are included in pharmaceutical compositions aimed at treating diseases associated with ErbBs, especially cancer.

Another significant patent involves triazolo-pyrimidine compounds targeting adenosine receptors, particularly A1 and A2 (especially A2a). This innovation is crucial for developing pharmaceutical compositions that utilize these compounds as active ingredients for treating adenosine receptor-associated diseases, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), prostate cancer, and breast cancer.

Career Highlights

Throughout his career, Zhenfan Yang has worked with leading pharmaceutical companies, including Dizal Pharmaceutical Co., Ltd. and AstraZeneca. His role in these organizations has been pivotal in advancing pharmaceutical research and innovation, focusing on the development of targeted therapies.

Collaborations

Zhenfan has collaborated with notable professionals in the industry, including Xiaolin Zhang and Qingbei Zeng. These partnerships have enriched his research and fostered advancements in the treatment of serious health conditions.

Conclusion

Zhenfan Yang's contributions to the pharmaceutical field through his patented innovations highlight his commitment to improving health outcomes. His work in developing targeted therapies positions him as a key figure in the ongoing battle against cancer and related diseases. His innovations continue to hold promise for patients worldwide.

Profile summary based on public USPTO records.